NCT03513900

Non-invasive Methods to Predict PHG in Cirrhosis

Completed Last updated 12 June 2019

What this trial tests

trial in Cirrhosis in 115 participants. Completed in 20 April 2019.

Timeline

6 March 2018

Primary endpoint
20 December 2018

20 April 2019

Quick facts

Lead sponsor	Second Affiliated Hospital of Xi'an Jiaotong University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	115
Start date	6 March 2018
Primary completion	20 December 2018
Estimated completion	20 April 2019
Sites	1 location across China

Conditions studied

• Cirrhosis — all drugs for Cirrhosis →

Sponsor

Second Affiliated Hospital of Xi'an Jiaotong University

Who can join

Adults 18 to 80, any sex, with Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Portal hypertensive gastropathy (PHG) is used to describe the endoscopic appearance of gastric mucosa in patients with cirrhotic portal hypertension, with a characteristic mosaic-like pattern with or without red spots. The severity of PHG can vary from mild to severe, and patients with PHG are at an increased risk of acute and chronic gastrointestinal bleeding. According to the study by Kim et al, severe PHG showed a significantly high-risk of mortality and reduced expected survival time than none or mild PHG. Therefore, we need to detect PHG as soon as possible.However, as an invasive examination, endoscopy examination may massive gastrointestinal bleeding or gastric perforation. Most patients are afraid and disable to tolerate it, which significantly reduces the real morbidity of PHG and delays the time for diagnosis and treatment. Therefore, there is a need to find effective non-invasive methods that can predict patients with PHG in the early stage, especially which require treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.